The Impact of Multidisciplinary Discussion (MDD) in the Diagnosis and Management of Fibrotic Interstitial Lung Diseases
- PMID: 32879642
- PMCID: PMC7448233
- DOI: 10.1155/2020/9026171
The Impact of Multidisciplinary Discussion (MDD) in the Diagnosis and Management of Fibrotic Interstitial Lung Diseases
Abstract
Accurate diagnosis of interstitial lung disease (ILD) is crucial for management and prognosis but can be challenging even for experienced clinicians. Expert multidisciplinary discussion (MDD) is considered the reference standard for ILD diagnosis; however, there remain concerns regarding lack of validation studies and relative limited information on the impact of MDD in real-life clinical practice. The goal of this study was to assess the effect of MDD in providing a specific ILD diagnosis, changing the diagnosis provided upon referral, and to determine how often and in which way MDD altered management. Material and Methods. Retrospective observational study in an ILD referral tertiary academic center. MDD diagnoses were categorized as specific, provisional, and unclassifiable ILD. Pre-MDD and MDD diagnoses were compared for change in diagnosis and concordance rates for specific diagnoses. Relevant change in management including initiation or change in pharmacological treatment, referral to surgical biopsy, and nonpharmacological management were recorded. Results. 126 cases were included (79M, 47F, 36-93 years, mean 70 y). Specific MDD diagnosis was provided in 62% (78/126); 12% (15/126) had provisional diagnosis, and 21% (27/126) was unclassifiable. Overall agreement for specific pre-MDD and MDD diagnosis was 41% (52/126) and 80% for idiopathic pulmonary fibrosis (IPF) diagnosis. MDD altered diagnosis in 37% (47/126) and changed management in 39% (50/126). Amongst concordant diagnoses, management was altered in 46% (24/52). In summary, MDD provided a specific diagnosis discordant with pre-MDD diagnosis in a significant proportion of cases and was particularly valuable in the diagnosis of non-IPF ILD. MDD often altered management and had relevant impact on management even in cases with concordant pre-MDD diagnosis.
Copyright © 2020 Ghofran Ageely et al.
Conflict of interest statement
Ghofran Ageely, Nha Voduc, and Saly Zahra declare that they have no conflicts of interest. Carolina Souza received consultant fees and honorarium from Pfizer, Boehringer–Ingelheim, AstraZeneca, and Hoffmann-La Roche, an educational grant from Boehringer–Ingelheim, is a member of the advisory board of AstraZeneca and Boehringer–Ingelheim. Kaissa De Boer received consultant fees and honorarium from Boehringer–Ingelheim and Hoffmann-La Roche and chair funding support from Boehringer–Ingelheim. Marcio Gomes received educational grants from Pfizer, BMS, Merck, AstraZeneca, Roche, Eli Lilly, and Boehringer–Ingelheim and honoraria from Amgen, AstraZeneca, Merck, and Roche.
Figures

References
-
- American Journal of Respiratory and Critical Care Medicine. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. American Journal of Respiratory and Critical Care Medicine. 2002;165(2):277–304. doi: 10.1164/ajrccm.165.2.ats01. - DOI - PubMed
-
- Travis W. D., Costabel U., Hansell D. M., et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine. 2013;188(6):733–748. doi: 10.1164/rccm.201308-1483st. - DOI - PMC - PubMed